Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Accounts Receivable are created when a customer has received a product but has not yet paid for that product. International Biotechnology Trust's accounts receivables for the quarter that ended in Feb. 2026 was £ Mil.
Accounts receivable can be measured by Days Sales Outstanding.
International Biotechnology Trust's Days Sales Outstanding for the quarter that ended in Feb. 2026 was 0.00.
In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. International Biotechnology Trust's Net-Net Working Capital per share for the quarter that ended in Feb. 2026 was £-0.91.
International Biotechnology Trust Accounts Receivable Explanation
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.
International Biotechnology Trust's Days Sales Outstanding for the quarter that ended in Feb. 2026 is calculated as:
2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), International Biotechnology Trust's accounts receivable are only considered to be worth 75% of book value:
International Biotechnology Trust's Net-Net Working Capital Per Share for the quarter that ended in Feb. 2026 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.
If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.
Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.
International Biotechnology Trust Accounts Receivable Related Terms
International Biotechnology Trust Accounts Receivable Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
International Biotechnology Trust Accounts Receivable Chart
International Biotechnology Trust (LSE:IBT) has a Accounts Receivable of £ Mil as of Feb. 2026. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on International Biotechnology Trust and its competitors.
Is International Biotechnology Trust's Accounts Receivable too high?
International Biotechnology Trust's current Accounts Receivable is £ Mil. Overall, International Biotechnology Trust has a GF Score™ of 42/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does International Biotechnology Trust's Accounts Receivable compare to VRTX and REGN?
International Biotechnology Trust's Accounts Receivable of £ Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Receivable for a Biotechnology company?
A good Accounts Receivable depends on the Biotechnology industry context. However, Accounts Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Receivable mean?
A high Accounts Receivable can signal that a stock is expensive relative to its fundamentals. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on International Biotechnology Trust and its competitors. International Biotechnology Trust's current Accounts Receivable is £ Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is International Biotechnology Trust stock overvalued right now?
Based on GuruFocus' analysis, International Biotechnology Trust (LSE:IBT) is currently considered Significantly Undervalued. The stock's GF Value™ is £28.13, compared to a current price of £11.10 — trading 60.5% below its estimated fair value. The current Accounts Receivable is £ Mil. International Biotechnology Trust's overall GF Score™ is 42/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Receivable calculated?
Accounts Receivable is calculated from a company's financial statements. For International Biotechnology Trust (LSE:IBT), the current Accounts Receivable is £ Mil as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is International Biotechnology Trust (LSE:IBT) Overvalued in 2026?
Based on GuruFocus' analysis, International Biotechnology Trust stock appears to be undervalued.
The current stock price of £11.10 is trading 60.5% below its estimated GF Value™ of £28.13.
GuruFocus considers International Biotechnology Trust to be Significantly Undervalued.
Key valuation signals for LSE:IBT:
Accounts Receivable: £ Mil
GF Value™: £28.13 vs. price of £11.10 (60.5% below fair value)
No single metric tells the full story. See the LSE:IBT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
International Biotechnology Trust PLC is an investment trust company. It aims at achieving long-term capital growth by investing in biotechnology and other life sciences companies. It seeks to achieve its objective by investing in a diversified portfolio of companies which has good growth prospects. It focuses on investments in biotechnology companies which are engaged in on drug discovery and development, medical devices companies and healthcare services provider. The invests in various financial instruments such as equities, index-linked securities, debt securities, cash deposits, money market instruments ,and foreign currency exchange transactions. Its revenue comprises of dividend, interest and other income from investment made.
42GF Score
Get the complete analysis for LSE:IBT
Accounts Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:IBT has been successfully added to your 
